Dialysis heavyweights punch well in second quarter
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences says net sales increased by 4%, excluding the effect of foreign exchange and divested businesses. In the company's cardiac surgery division, sales were $85 million, up 10%. Growth continues to be led by robust sales of its pericardial tissue valve products. Critical care sales rose 7% to $54 million. Edwards says it is benefiting from the continued trend of customers to more advanced technology catheter products. Vascular sales fell 3% to $13 million. The company says it is on track to re-enter the European market with its Lifepath AAA Endovascular graft system, as well as resuming US clinical trials of the product, by the end of the year. Edwards voluntarily halted European sales and US clinical trials of the device after it found a fracture in the product's wireform in April 2000 (see Clinica No 906, p 1). Edwards expects a 20% increase in net income for the full year.